Çocukluk çağı epilepsilerinde lamotrigin tedavisi
Küçük Resim Yok
Tarih
2001
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Bu çalışmada epilepsi tanısı almış 41 çocukta Lamotrigin'in etkinliği araştırıldı. Hastalarımızın 30'u erkek, 11'i kızdı. Hastaların ortalama tanı yaşı 4,5 yıl (2 ay-12 yıl) ve lamotrigin başlama yaşı 9,1 yıl (10 ay-17 yıl) idi. Nöbet tipleri Uluslararası Epilepsi ile Savaş Derneği kriterlerine göre; kompleks parsiyel nöbet (n: 16), jeneralize tonik klonik nöbet (n:11), basit parsiyel nöbet (n:5), absans (n:4), sekonder jeneralize nöbet (n:3), infantil spazm (n:2) olarak sınıflandırıldı. Tedaviye yanıt 4., 12. ve 24. ayda değerlendirildi. Lamotrigin 9 olguda monoterapi, 32 olguda almakta olduğu tedaviye ek olarak uygulandı. Monoterapi alan olguların 5'inde tam nöbet kontrolü sağlandı. Onikinci ayın sonunda nöbet sayısında %50'den fazla azalma jeneralize tonik klonik nöbetlerin %72.7'sinde, absans nöbetlerin %75'inde, basit parsiyel nöbetlerin %60'ında, kompleks parsiyel nöbetlerin %43.8'inde ve sekonder jeneralize nöbetlerin %100'ünde gözlendi. En iyi yanıtlar sekonder jeneralize, absans ve jeneralize tonik klonik nöbetleri olan hastalarda elde edildi. Tedaviye yanıtsızlık nedeni ile 12. ayın sonunda 9 hastada tedavi kesildi. Başlangıçta tedaviye yanıt veren infantil spazmlı ve sekonder jeneralize nöbetleri olan iki hastada 18. ve 24.aylarda tolerans gelişti. Sadece 3 olguda tedavi sonlandırılmasına gerek duyulmayan döküntü, karaciğer fonksiyon testlerinde yükselme ve ajitasyon gibi yan etkiler görüldü. Lamotrigin'in çocukluk çağı epilepsilerinde güvenle kullanılabilecek, etkili bir antiepileptik ilaç olduğu düşünüldü.
The efficacy of Lamotrigine was evaluated in 41 epileptic children (30 males, 11 females) followed up in Pediatric Neurology department. the mean age for epilepsy diagnosis was 4.5±3.4 years (2 months-12 years) and for starting Lamotrigine (LTG) was 9.1±4.4 years (10 months-17 years). Seizure types were classified in according to International League Against Epilepsy criteria: complex partial seizure (n:16), simple partial seizure (n:5), secondary generalized seizure (n:3), generalized tonic clonic seizure (n:11), absence seizure (n:4), infantile spasms (n:2). the therapy response was evaluated at the 4th, 12th, 24th month. Nine and 32 patients received LTG as monotherapy and add-on therapy respectively. We achieved more than 50% reduction in seizure frequency in 43.8% of complex partial seizures, 60% of simple partial seizures, 100% of secondary generalized seizures, 72.7% of generalized tonic clonic seizures, 75% of absence seizures and 50% of the infantile spasms at the end of 12th month. Tolerance was developed in two patients at the end of 18th and 24th months. Totally 9 patients were dropped out after 12 months because of nonresponsiveness. Adverse effects of LTG were rare. in three patients rash, elevation of liver function tests and agitation were the adverse effects seen without requirement of stopping the therapy.
The efficacy of Lamotrigine was evaluated in 41 epileptic children (30 males, 11 females) followed up in Pediatric Neurology department. the mean age for epilepsy diagnosis was 4.5±3.4 years (2 months-12 years) and for starting Lamotrigine (LTG) was 9.1±4.4 years (10 months-17 years). Seizure types were classified in according to International League Against Epilepsy criteria: complex partial seizure (n:16), simple partial seizure (n:5), secondary generalized seizure (n:3), generalized tonic clonic seizure (n:11), absence seizure (n:4), infantile spasms (n:2). the therapy response was evaluated at the 4th, 12th, 24th month. Nine and 32 patients received LTG as monotherapy and add-on therapy respectively. We achieved more than 50% reduction in seizure frequency in 43.8% of complex partial seizures, 60% of simple partial seizures, 100% of secondary generalized seizures, 72.7% of generalized tonic clonic seizures, 75% of absence seizures and 50% of the infantile spasms at the end of 12th month. Tolerance was developed in two patients at the end of 18th and 24th months. Totally 9 patients were dropped out after 12 months because of nonresponsiveness. Adverse effects of LTG were rare. in three patients rash, elevation of liver function tests and agitation were the adverse effects seen without requirement of stopping the therapy.
Açıklama
Anahtar Kelimeler
Pediatri
Kaynak
Ege Pediatri Bülteni
WoS Q Değeri
Scopus Q Değeri
Cilt
8
Sayı
4
